At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Bone Marrow Aspiration and Biopsy, and 9 other interventions for Advanced Malignant Solid Neoplasm and 31 related conditions. Active but no longer recruiting, targeting 20 participants across 116 sites in 2 countries.
Signals
Detailed Summary
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.
Study Details
Timeline
Arms & Interventions
Patients receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
Interventions
Undergo blood sample collection
Undergo a bone marrow aspiration and/or biopsy
Undergo a bone scan
Undergo a CT scan
Given PO
Correlative studies
Undergo MRI
Correlative studies
Undergo a PET scan
Undergo radionuclide imaging
Undergo an x-ray